1. Home
  2. SGMT vs RENE Comparison

SGMT vs RENE Comparison

Compare SGMT & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • RENE
  • Stock Information
  • Founded
  • SGMT 2006
  • RENE 2021
  • Country
  • SGMT United States
  • RENE United States
  • Employees
  • SGMT N/A
  • RENE N/A
  • Industry
  • SGMT
  • RENE Blank Checks
  • Sector
  • SGMT
  • RENE Finance
  • Exchange
  • SGMT Nasdaq
  • RENE Nasdaq
  • Market Cap
  • SGMT 159.0M
  • RENE 151.4M
  • IPO Year
  • SGMT 2023
  • RENE 2022
  • Fundamental
  • Price
  • SGMT $4.39
  • RENE $11.66
  • Analyst Decision
  • SGMT Buy
  • RENE
  • Analyst Count
  • SGMT 6
  • RENE 0
  • Target Price
  • SGMT $23.00
  • RENE N/A
  • AVG Volume (30 Days)
  • SGMT 1.2M
  • RENE 4.1K
  • Earning Date
  • SGMT 11-13-2024
  • RENE 01-01-0001
  • Dividend Yield
  • SGMT N/A
  • RENE N/A
  • EPS Growth
  • SGMT N/A
  • RENE 42.92
  • EPS
  • SGMT N/A
  • RENE 0.43
  • Revenue
  • SGMT N/A
  • RENE N/A
  • Revenue This Year
  • SGMT N/A
  • RENE N/A
  • Revenue Next Year
  • SGMT N/A
  • RENE N/A
  • P/E Ratio
  • SGMT N/A
  • RENE $26.90
  • Revenue Growth
  • SGMT N/A
  • RENE N/A
  • 52 Week Low
  • SGMT $2.39
  • RENE $11.00
  • 52 Week High
  • SGMT $20.71
  • RENE $11.78
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 44.30
  • RENE 48.91
  • Support Level
  • SGMT $4.06
  • RENE $11.56
  • Resistance Level
  • SGMT $7.38
  • RENE $11.70
  • Average True Range (ATR)
  • SGMT 0.63
  • RENE 0.02
  • MACD
  • SGMT -0.11
  • RENE -0.00
  • Stochastic Oscillator
  • SGMT 9.94
  • RENE 45.45

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: